Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVolex Regulatory News (VLX)

Share Price Information for Volex (VLX)

Share Price is delayed by 15 minutes
Get Live Data
601.00    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 3.00 (0.50%)
Market Cap: £1.10b
VLX Live PriceLast checked at - London Stock Exchange

Intraday Volex Share Chart

Full Year Trading Update

18 Apr 2023 07:00

RNS Number : 4982W
Volex PLC
18 April 2023
 

 

Volex plc

 

("Volex", the "Group", or the "Company")

 

Full Year Trading Update

 

Strong organic growth with revenue and profit ahead of expectations

 

Volex (AIM: VLX), the specialist integrated manufacturer of critical power and data transmission products, today issues an update on trading for the 52 weeks ended 2 April 2023 (the "Year" or "FY2023").

 

Full year trading ahead of market expectations

 

Volex has continued its positive momentum and demonstrated further progress during the Year, reflecting its compelling positions in attractive markets with strong structural growth characteristics.

 

Revenue is now expected to be at least $710 million, representing an increase of at least 15.5% compared with the prior year. Underlying operating profit is now expected to be at least $66 million, at least 17.4% higher than the prior year, with both revenue and underlying operating profit ahead of market expectations1, 2.

 

An increase in gross margins and continued cost control improvements is expected to deliver a strengthening in underlying operating margins to 9.3% (FY2022: 9.1%). The Group has delivered margins within its targeted range for three years, managing inflationary cost challenges and demonstrating the strong competitive positioning.

 

Operating free cash flow in the second half of the Year was substantially higher than the first half. After capital investment, dividend payments and acquisition consideration of approximately $46 million in the Year, pre-IFRS 16 net debt is expected to be approximately $76 million. This is a reduction of $22 million since the half year and represents a covenant leverage of 1.0x3, comfortably below the Group's target leverage corridor.

 

Continued outperformance of underlying markets provides strong momentum into FY2024

 

Against a volatile backdrop in FY2023, Volex delivered strong organic growth, ahead of its underlying markets, which has been driven by continued execution of the Group's commercial strategy which focuses on:

 

· Targeting structural growth markets - with the Electric Vehicles, Complex Industrial Technology and Medical sectors all delivering strong constant currency organic revenue growth in FY2023. Pleasingly, the adverse impact of post-pandemic demand normalisation in the Consumer Electricals sector is being largely offset by market share gains

 

· Leveraging the Group's global footprint - which is enabling the Group to benefit from heightened levels of demand in a number of territories as a result of customers re-configuring supply chains to focus on partners with high service levels and local facilities

 

· Expanding the Group's range of capabilities - through targeted investment the Group has continued to expand its offering which has led to a high level of new project wins with both new and existing customers

 

Volex is well positioned to continue investing in sustainable organic growth with a robust balance sheet and healthy cash generation. The Group has an active acquisition pipeline of value enhancing opportunities, which will support the achievement of the five-year strategy to grow revenues to $1.2 billion by the end of FY2027.

 

Nat Rothschild, Executive Chairman, said: "I am delighted with the strong organic growth performance delivered by the business during the period. We continue to deliver against the long-term, strategic growth plan that we unveiled last year and I firmly believe that Volex's diverse global footprint, ongoing investment plans and reputation for excellence will continue to drive ongoing outperformance versus our competitors. This, combined with our robust balance sheet and healthy cash generation, means that the Group is well positioned as we enter the new financial year."

 

-ENDS-

 

 

For further information please contact:

Volex plc

Nat Rothschild, Executive Chairman

Jon Boaden, Chief Financial Officer

+44 (0)7747 488785

investor.relations@volex.com

 

Singer Capital Markets - Nominated Adviser & Joint Broker

Shaun Dobson

George Tzimas

+44 (0)20 7496 3000

 

HSBC Bank plc - Joint Broker

Simon Alexander

Joe Weaving

+44 (0)20 7991 8888

 

Powerscourt - Media Enquiries

James White

Nicholas Johnson 

 

+44 (0)20 7250 1446

 

Notes:

1. Underlying operating profit is before adjusting items which are one-off in nature and significant (such as restructuring costs, impairment charges or acquisition-related costs), the amortisation and impairment of acquired intangible assets and share-based payment charges. This trading update is based upon unaudited management accounts information. Forward-looking statements have been made by the Directors in good faith using information available up until the date that they approved this statement. Forward-looking statements should be regarded with caution because of the inherent uncertainties in economic trends and business risks.

 

2. The Company has compiled forecasts from five analysts with current market forecasts for the 52 weeks ending 2 April 2023 for revenue to be in the range of $690.5 million to $695.0 million, with a consensus of $692.9 million, and for underlying operating profit to be in the range of $62.3 million to $64.0 million, with a consensus of $62.9 million.

 

3. Covenant leverage represents the ratio of net debt, excluding operating lease liabilities, to EBITDA excluding the impact of right of use amortisation arising on operating lease arrangements. This measure is aligned with the covenant calculations used for external debt facilities.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFLDSDIDLIV
Date   Source Headline
26th May 20263:00 pmRNSNotice of Results
15th May 20267:45 amRNSHolding(s) in Company
11th May 20267:00 amRNSHolding(s) in Company
30th Apr 20263:07 pmRNSHolding(s) in Company
22nd Apr 20267:00 amRNSCapital Markets Event
7th Apr 20267:00 amRNSLaunch of £40 million Share Buyback Programme
7th Apr 20267:00 amRNSUpdate on Move to the Main Market
26th Mar 20265:30 pmRNSHolding(s) in Company
25th Mar 20267:00 amRNSTrading update and Notice of Capital Markets Event
20th Mar 20262:00 pmRNSDirector/PDMR Shareholding
10th Feb 20267:45 amRNSHolding(s) in Company
2nd Feb 20264:45 pmRNSDirector/PDMR Shareholding
30th Jan 20264:30 pmRNSDirector/PDMR Shareholding
21st Jan 20267:00 amRNSTrading Update
12th Jan 20265:30 pmRNSDirector/PDMR Shareholding
8th Jan 20262:00 pmRNSDirector/PDMR Shareholding
5th Jan 20263:00 pmRNSIssue of Equity and Total Voting Rights
15th Dec 20257:00 amRNSDirector/PDMR Shareholding
11th Dec 20255:55 pmRNSDirector/PDMR Shareholding
4th Dec 202511:30 amRNSScrip Reference Price
12th Nov 20257:00 amRNSAppointment of Non-Executive Chair and CEO
12th Nov 20257:00 amRNSHalf-year Report
20th Oct 20257:00 amRNSNotice of Results
16th Oct 20257:00 amRNSHalf Year Trading Update
29th Sep 20251:25 pmRNSHolding(s) in Company
18th Sep 20257:00 amRNSHolding(s) in Company
15th Sep 202511:30 amRNSDirector/PDMR Shareholding
15th Sep 202510:15 amRNSHolding(s) in Company
5th Sep 20259:00 amRNSDirector/PDMR Shareholding
1st Sep 20251:00 pmRNSIssue of Equity and Total Voting Rights
7th Aug 20254:35 pmRNSResult of AGM
7th Aug 202512:30 pmRNSScrip Reference Price
7th Aug 20257:00 amRNSAGM Statement
4th Aug 20252:00 pmRNSHolding(s) in Company
7th Jul 20254:35 pmRNSPDMR / PCA Shareholding
4th Jul 202511:00 amRNSNotice of AGM and Publication of Annual Report
26th Jun 20257:00 amRNSPreliminary Group Results FY2025
2nd Jun 20257:00 amRNSNotice of Results and Investor Presentation
16th Apr 20252:00 pmRNSDirector/PDMR Shareholding
16th Apr 20251:00 pmRNSDirector/PDMR Shareholding
10th Apr 20256:00 pmRNSDirector/PDMR Shareholding
7th Apr 20257:00 amRNSFull Year Trading Update
19th Mar 20253:30 pmRNSDirector/PDMR Shareholding
13th Mar 20255:45 pmRNSHolding(s) in Company
27th Jan 20257:00 amRNSChange of Adviser
27th Jan 20257:00 amRNSTrading Update
16th Jan 20251:15 pmRNSDirector/PDMR Shareholding
16th Jan 20251:15 pmRNSDirector/PDMR Shareholding
3rd Jan 20257:00 amRNSDeferred Consideration for Acquisition
19th Dec 20247:00 amRNSForm 8.3 - Volex PLC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.